Radiation Therapy for Grade 3 Gliomas: Correlation of MRI Findings With Prognosis.
glioma
grade 3
high grade glioma
radiotherapy
risk factors
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
accepted:
04
08
2021
entrez:
13
9
2021
pubmed:
14
9
2021
medline:
14
9
2021
Statut:
epublish
Résumé
Background and objective Postoperative radiotherapy is usually indicated for both grade 3 glioma and grade 4 glioblastoma. However, the treatment results and tumor features of grade 3 glioma clearly differ from those of glioblastoma. There is limited information on outcomes and tumor progression for grade 3 glioma. In this study, we evaluate the result of postoperative radiotherapy for grade 3 glioma and focus on the correlation of MRI findings with prognosis. Methods In this study, 99 of 110 patients with grade 3 glioma who received postoperative radiotherapy and were followed up for more than one year were retrospectively analyzed. The total irradiation dose was 60.0 Gy in 30 fractions, and daily temozolomide or two cycles of nimustine (ACNU) was concurrently administered during radiotherapy. The median follow-up period was 46 months (range: 2-151 months). Results In multivariate analysis, pathology [anaplastic oligodendroglioma (AO) vs. anaplastic astrocytoma (AA)], the status of surgical resection (biopsy vs. partial resection or more), and contrast enhancement (enhanced by MRI image or not) were significant factors for overall survival (OS). The five-year OS for AO vs. AA cases were 76.8% vs. 46.1%, total to partial resection vs. biopsy cases were 72.7% vs. 21.0%, and non-enhanced vs. enhanced cases were 82.5% vs. 45.6%, respectively. In multivariate analysis, the status of surgical resection and longer extension of preoperative edema (PE) were significant factors for progression-free survival (PFS). The five-year PFS for the total to partial resection vs. biopsy cases were 52.9% vs. 10.7%, and non-extensive PE vs. extensive PE (EPE) cases were 62.2% vs. 19.1%, respectively. Conclusion Our results suggest that a contrast-enhanced tumor on MRI and a longer PE may also be significantly associated with OS and PFS among grade 3 glioma patients.
Identifiants
pubmed: 34513462
doi: 10.7759/cureus.16887
pmc: PMC8416380
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e16887Informations de copyright
Copyright © 2021, Mizumoto et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Clin Oncol. 1993 Jul;11(7):1316-21
pubmed: 8315428
Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):98-105
pubmed: 19695794
Neurochirurgie. 2005 Sep;51(3-4 Pt 2):247-53
pubmed: 16292168
Radiother Oncol. 2010 Dec;97(3):377-81
pubmed: 20855119
J Neurooncol. 1997 Aug;34(1):61-78
pubmed: 9210053
J Clin Oncol. 2002 Mar 1;20(5):1375-82
pubmed: 11870182
Neuro Oncol. 2009 Apr;11(2):176-82
pubmed: 18697954
J Clin Oncol. 2009 Sep 1;27(25):4150-4
pubmed: 19636000
Cancer Treat Rep. 1983 Feb;67(2):121-32
pubmed: 6337710
N Engl J Med. 2009 Feb 19;360(8):765-73
pubmed: 19228619
AJNR Am J Neuroradiol. 2005 Apr;26(4):784-90
pubmed: 15814921
Neuro Oncol. 2010 May;12(5):490-9
pubmed: 20156805
Clin Transl Oncol. 2018 Jul;20(7):937
pubmed: 29858734
Radiother Oncol. 2017 Nov;125(2):248-257
pubmed: 29056290
Neuro Oncol. 2016 Nov;18(11):1529-1537
pubmed: 27370396
Asia Pac J Clin Oncol. 2013 Sep;9(3):220-5
pubmed: 23279669
J Clin Oncol. 2013 Jan 20;31(3):337-43
pubmed: 23071247
Lancet. 2017 Oct 7;390(10103):1645-1653
pubmed: 28801186
Curr Treat Options Oncol. 2018 Oct 25;19(12):61
pubmed: 30361986
J Neurooncol. 2016 Oct;130(1):165-170
pubmed: 27535747
J Neurooncol. 1998 Nov;40(2):161-70
pubmed: 9892098
J Neurooncol. 1997 Aug;34(1):37-59
pubmed: 9210052
Radiat Oncol. 2020 Dec 17;15(1):282
pubmed: 33334378
J Neurosurg. 1978 Sep;49(3):333-43
pubmed: 355604